Bristol Myers Squibb Merges Research and Development Teams Under CMO Cristian Massacesi
Bengaluru: Bristol Myers Squibb said on Thursday it will combine its scientific and clinical expertise teams into an end-to-end research and development department under current Chief Medical Officer Cristian Massacesi, effective January 1, 2027.
Current Chief Research Officer Robert Plenge will leave in March 2027 after the transition.
"Bringing Research and Development together as one organization is an important step in our work to position BMS for long-term growth," said CEO Christopher Boerner.
Analysts are closely watching Bristol's drug development pipeline for clues on growth.
"Under Cristian's leadership, this new structure will more closely connect our scientific and clinical expertise across R&D, accelerate decision making and ultimately enhance portfolio execution," Boerner said.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.